Patents by Inventor R. Anthony Williamson
R. Anthony Williamson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110250630Abstract: Provided herein are hybrid polypeptides that specifically bind to a disease-associated isoform of a polypeptide involved in diseases of protein aggregation. The hybrid polypeptides can be used for diagnosis and treatment of such diseases. In a particular embodiment, a hybrid protein that specifically binds to the infectious form of a prion (PrPSc) is provided.Type: ApplicationFiled: April 5, 2011Publication date: October 13, 2011Inventors: Dennis R. Burton, Gianluca Moroncini, R. Anthony Williamson
-
Publication number: 20110135645Abstract: The present invention discloses methods for generating antibodies to human metapneumovirus (HMPV) polypeptides, including antibodies that immunospecifically bind to a HMPV F-protein. The invention also discloses methods for preventing, treating, or ameliorating symptoms associated with HMPV infection.Type: ApplicationFiled: October 4, 2007Publication date: June 9, 2011Applicant: The Scripps Research InstituteInventors: R. Anthony Williamson, Zhifeng Chen, Pietro Paolo Sanna, Dennis R. Burton, James Crowe, John V. Williams
-
Patent number: 7939641Abstract: Provided herein are hybrid polypeptides that specifically bind to a disease-associated isoform of a polypeptide involved in diseases of protein aggregation. The hybrid polypeptides can be used for diagnosis and treatment of such diseases. In a particular embodiment, a hybrid protein that specifically binds to the infectious form of a prion (PrPSc) is provided.Type: GrantFiled: April 8, 2003Date of Patent: May 10, 2011Assignee: The Scripps Research InstituteInventors: Dennis R. Burton, Gianluca Moroncini, R. Anthony Williamson
-
Patent number: 7094553Abstract: The present invention provides antibodies that specifically bind with a high degree of binding affinity to a native ungulate PrPC and/or a denatured ungulate PrPSc, but not to a native ungulate PrPSc. Preferred antibodies find native bovine PrPC and treated PrPSc but not native bovine PrPSc and can be used in an assay to determine if a sample is infected with infectious prions, i.e. PrPSc.Type: GrantFiled: January 30, 2003Date of Patent: August 22, 2006Assignees: The Regents of the University of California, The Scripps Research InstituteInventors: Stanley B. Prusiner, Jiri G. Safar, R. Anthony Williamson, Dennis R. Burton
-
Patent number: 7060799Abstract: The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay.Type: GrantFiled: February 19, 2002Date of Patent: June 13, 2006Assignee: The Scripps Research InstituteInventors: Dennis R. Burton, Roberto Burioni, R. Anthony Williamson, Pietro P. Sanna
-
Patent number: 7052675Abstract: Antibodies are disclosed which specifically bind to native PrPSc in situ. Preferred antibodies bind only to the native PrPSc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a particular isoform of human PrPSc. Preferred antibodies of the invention are (1) produced by phage display methodology, (2) bind specifically to native PrPSc, (3) neutralizes the infectivity of prions, (4) bind to PrPSc in situ and (5) bind 50% or more of PrPSc in a liquid flowable sample. Antibodies of the invention can be bound to a substrate and used to assay a sample (which has any PrPc denatured via proteinase K) for the presence of PrPSc of a specific species which PrPSc is associated with disease. Antibodies which specifically bind to human PrPSc can be labeled and injected carrying out an in vivo diagnostic test to determine if the human is infected with prions associated with disease.Type: GrantFiled: December 29, 2004Date of Patent: May 30, 2006Assignees: The Regents of the University of California, The Scripps Research InstituteInventors: Stanley B. Prusiner, R. Anthony Williamson, Dennis R. Burton
-
Patent number: 6858397Abstract: Antibodies are disclosed which specifically bind to native PrPSc in situ. Preferred antibodies bind only to the native PrPSc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a particular isoform of human PrPSc. Preferred antibodies of the invention are (1) produced by phage display methodology, (2) bind specifically to native PrPSc, (3) neutralizes the infectivity of prions, (4) bind to PrPSc in situ and (5) bind 50% or more of PrPSc in a liquid flowable sample. Antibodies of the invention can be bound to a substrate and used to assay a sample (which has any PrPc denatured via proteinase K) for the presence of PrPSc of a specific species which PrPSc is associated with disease. Antibodies which specifically bind to human PrPSc can be labeled and injected carrying out an in vivo diagnostic test to determine if the human is infected with prions associated with disease.Type: GrantFiled: May 9, 2003Date of Patent: February 22, 2005Assignees: The Regents of the University of California, The Scripps Research InstituteInventors: Stanley B. Prusiner, R. Anthony Williamson, Dennis R. Burton
-
Publication number: 20030228303Abstract: Antibodies are disclosed which specifically bind to native PrPSc in situ. Preferred antibodies bind only to the native PrPSc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a particular isoform of human PrPSc. Preferred antibodies of the invention are (1) produced by phage display methodology, (2) bind specifically to native PrPSc, (3) neutralizes the infectivity of prions, (4) bind to PrPSc in situ and (5) bind 50% or more of PrPSc in a liquid flowable sample. Antibodies of the invention can be bound to a substrate and used to assay a sample (which has any PrPc de-natured via proteinase K) for the presence of PrPSc of a specific species which PrPSc is associated with disease. Antibodies which specifically bind to human PrPSc can be labeled and injected carrying out an in vivo diagnostic test to determine if the human is infected with prions associated with disease.Type: ApplicationFiled: May 9, 2003Publication date: December 11, 2003Applicant: The Regents of the University of California and The Scripps Research InstituteInventors: Stanley B. Prusiner, R. Anthony Williamson, Dennis R. Burton
-
Publication number: 20030215880Abstract: Provided herein are hybrid polypeptides that specifically bind to a disease-associated isoform of a polypeptide involved in diseases of protein aggregation. The hybrid polypeptides can be used for diagnosis and treatment of such diseases. In a particular embodiment, a hybrid protein that specifically binds to the infectious form of a prion (PrPSc) is provided.Type: ApplicationFiled: April 8, 2003Publication date: November 20, 2003Inventors: Dennis R. Burton, Gianluca Moroncini, R. Anthony Williamson
-
Publication number: 20030143224Abstract: The present invention provides antibodies that specifically bind with a high degree of binding affinity to a native ungulate PrPC and/or a denatured ungulate PrPSc, but not to a native ungulate PrPSc. Preferred antibodies find native bovine PrPC and treated PrPSc but not native bovine PrPSc and can be used in an assay to determine if a sample is infected with infectious prions, i.e. PrPSc.Type: ApplicationFiled: January 30, 2003Publication date: July 31, 2003Inventors: Stanley B. Prusiner, Jiri G. Safar, R. Anthony Williamson, Dennis R. Burton
-
Patent number: 6562341Abstract: Antibodies are disclosed which specifically bind to native PrPSc in situ. Preferred antibodies bind only to the native PrPSc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a particular isoform of human PrPSc. Preferred antibodies of the invention are (1) produced by phage display methodology, (2) bind specifically to native PrPSc, (3) neutralizes the infectivity of prions, (4) bind to PrPSc in situ and (5) bind 50% or more of PrPSc in a liquid flowable sample. Antibodies of the invention can be bound to a substrate and used to assay a sample (which has any PrPc denatured via proteinase K) for the presence of PrPSc of a specific species which PrPSc is associated with disease. Antibodies which specifically bind to human PrPSc can be labeled and injected carrying out an in vivo diagnostic test to determine if the human is infected with prions associated with disease.Type: GrantFiled: August 30, 2001Date of Patent: May 13, 2003Assignees: The Regents of the University of California, The Scripps Research InstituteInventors: Stanley B. Prusiner, R. Anthony Williamson, Dennis R. Burton
-
Patent number: 6537548Abstract: The present invention provides antibodies that specifically bind with a high degree of binding affinity to a native ungulate PrPC and/or a denatured ungulate PrPSc, but not to a native ungulate PrPSc. Preferred antibodies find native bovine PrPC and treated PrPSc but not native bovine PrPSc and can be used in an assay to determine if a sample is infected with infectious prions, i.e. PrPSc.Type: GrantFiled: July 27, 2000Date of Patent: March 25, 2003Assignees: The Regents of the University of California, The Scripps Research InstituteInventors: Stanley B. Prusiner, Jiri Safar, R. Anthony Williamson, Dennis R. Burton
-
Publication number: 20020168629Abstract: The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay.Type: ApplicationFiled: February 19, 2002Publication date: November 14, 2002Applicant: The Scripps Research Institute, a California CorporationInventors: Dennis R. Burton, Roberto Burioni, R. Anthony Williamson, Pietro P. Sanna
-
Publication number: 20020150571Abstract: Antibodies are disclosed which specifically bind to native PrPSc in situ. Preferred antibodies bind only to the native PrPSc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a particular isoform of human PrPSc. Preferred antibodies of the invention are (1) produced by phage display methodology, (2) bind specifically to native PrPSc, (3) neutralizes the infectivity of prions, (4) bind to PrPSc in situ and (5) bind 50% or more of PrPSc in a liquid flowable sample. Antibodies of the invention can be bound to a substrate and used to assay a sample (which has any PrPc denatured via proteinase K) for the presence of PrPSc of a specific species which PrPSc is associated with disease. Antibodies which specifically bind to human PrPSc can be labeled and injected carrying out an in vivo diagnostic test to determine if the human is infected with prions associated with disease.Type: ApplicationFiled: August 30, 2001Publication date: October 17, 2002Inventors: Stanley B. Prusiner, R. Anthony Williamson, Dennis R. Burton
-
Patent number: 6376170Abstract: The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay.Type: GrantFiled: November 18, 1997Date of Patent: April 23, 2002Assignee: The Scripps Research InstituteInventors: Dennis R. Burton, Roberto Burioni, R. Anthony Williamson, Pietro P. Sanna
-
Patent number: 6372214Abstract: Antibodies are disclosed which specifically bind to native PrPSc in situ. Preferred antibodies bind only to the native PrPSc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a particular isoform of human PrPSc. Preferred antibodies of the invention are (1) produced by phage display methodology, (2) bind specifically to native PrPSc, (3) neutralizes the infectivity of prions, (4) bind to PrPSc in situ and (5) bind 50% or more of PrPSc in a liquid flowable sample. Antibodies of the invention can be bound to a substrate and used to assay a sample (which has any PrPSc denatured via proteinase K) for the presence of PrPSc of a specific species which PrPSc is associated with disease. Antibodies which specifically bind to human PrPSc can be labeled and injected carrying out an in vivo diagnostic test to determine if the human is infected with prions associated with disease.Type: GrantFiled: April 13, 2000Date of Patent: April 16, 2002Assignees: The Regents of the University of California, The Scripps Research InstituteInventors: Stanley B. Prusiner, R. Anthony Williamson, Dennis R. Burton
-
Patent number: 6290954Abstract: Antibodies are disclosed which specifically bind to native PrPSc in situ. Preferred antibodies bind only to the native PrPSc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a particular isoform of human PrPSc. Preferred antibodies of the invention are (1) produced by phage display methodology, (2) bind specifically to native PrPSc, (3) neutralizes the infectivity of prions, (4) bind to PrPSc in situ and (5) bind 50% or more of PrPSc in a liquid flowable sample. Antibodies of the invention can be bound to a substrate and used to assay a sample (which has any PrPc denatured via proteinase K) for the presence of PrPSc of a specific species which PrPSc is associated with disease. Antibodies which specifically bind to human PrPSc can be labeled and injected carrying out an in vivo diagnostic test to determine if the human is infected with prions associated with disease.Type: GrantFiled: March 6, 1998Date of Patent: September 18, 2001Assignee: The Scripps Research InstituteInventors: Stanley B. Prusiner, R. Anthony Williamson, Dennis R. Burton
-
Patent number: 5846533Abstract: Antibodies are disclosed which specifically bind to native PrP.sup.Sc in situ. Preferred antibodies bind only to the native PrP.sup.Sc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a particular isoform of human PrP.sup.Sc. Preferred antibodies of the invention are (1) produced by phage display methodology, (2) bind specifically to native PrP.sup.Sc, (3) neutralizes the infectivity of prions, (4) bind to PrP.sup.Sc in situ and (5) bind 50% or more of PrP.sup.Sc in a liquid flowable sample. Antibodies of the invention can be bound to a substrate and used to assay a sample (which has any PrP.sup.c denatured via proteinase K) for the presence of PrP.sup.Sc of a specific species which PrP.sup.Sc is associated with disease. Antibodies which specifically bind to human PrP.sup.Sc can be labeled and injected carrying out an in vivo diagnostic test to determine if the human is infected with prions associated with disease.Type: GrantFiled: September 13, 1996Date of Patent: December 8, 1998Assignees: The Regents of the University of California, The Scripps Research InstituteInventors: Stanley B. Prusiner, R. Anthony Williamson, Dennis R. Burton